Literature DB >> 9207463

Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells.

M Urashima1, G Teoh, D Chauhan, Y Hoshi, A Ogata, S P Treon, R L Schlossman, K C Anderson.   

Abstract

Interleukin-6 (IL-6) is a growth factor for multiple myeloma (MM) cells and can inhibit MM cell apoptosis. Our recent studies show that IL-6 facilitates MM cell growth via phosphorylation of retinoblastoma protein (pRB); however, the effects of IL-6 on those cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors (CDIs) that are known to regulate phosphorylation of pRB have not been defined in MM cells. In the present report, we cultured MM cell lines and patient cells with IL-6 and/or dexamethasone (Dex) and characterized changes in cell cycle; expression and association of cyclins, CDKs, and CDIs; and phosphorylation of pRB. Dex induced G1 growth arrest in MM cells, whereas IL-6 facilitated G1 to S phase transition; moreover, the effect of Dex was blocked by IL-6. p21WAF1 (p21) protein was constitutively expressed in the majority of MM cells independent of the status of p53. Its expression was upregulated by Dex and downregulated by IL-6; again, IL-6 inhibited the increase in p21 triggered by Dex. These alterations in p21 expression in MM cells were associated with changes in p21 binding to CDK2, CDK4, and CDK6; CDK2, CDK4, and CDK6 kinase activities; and phosphorylation of pRB. In contrast, expression of G1 cell cycle regulatory proteins, including p27KIP1, cyclin D2, and cyclin E, was not altered in MM cells cultured with Dex and/or IL-6. Finally, interferon-gamma (IFN-gamma) also induced G1 growth arrest and upregulated p21 protein expression; as with Dex, affects of IFN-gamma were inhibited by IL-6. Our results therefore show that changes in cell cycle distribution in MM cells triggered by Dex, IL-6, and IFN-gamma correlate with changes in p21 protein expression and implicate p21 in the coupling of Dex-, IL-6-, and IFN-gamma-related signals to G1 cell cycle regulation in MM cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207463

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Authors:  Salma Afifi; Angela Michael; Mahshid Azimi; Mabel Rodriguez; Nikoletta Lendvai; Ola Landgren
Journal:  Pharmacotherapy       Date:  2015-12       Impact factor: 4.705

2.  NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.

Authors:  Junwei Huang; Yi Zhou; Gregory S Thomas; Zhimin Gu; Ye Yang; Hongwei Xu; Guido Tricot; Fenghuang Zhan
Journal:  Clin Cancer Res       Date:  2015-07-08       Impact factor: 12.531

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

Review 4.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 5.  Molecular virology of Kaposi's sarcoma-associated herpesvirus.

Authors:  P S Moore; Y Chang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Authors:  Hiroshi Yasui; Teru Hideshima; Makoto Hamasaki; Aldo M Roccaro; Norihiko Shiraishi; Shaji Kumar; Pierfrancesco Tassone; Kenji Ishitsuka; Noopur Raje; Yu-Tzu Tai; Klaus Podar; Dharminder Chauhan; Lorenzo M Leoni; Sarath Kanekal; Gary Elliott; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

7.  Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells.

Authors:  Yijiang Shi; Tracy R Daniels-Wells; Patrick Frost; Jihye Lee; Richard S Finn; Carolyne Bardeleben; Manuel L Penichet; Michael E Jung; Joseph Gera; Alan Lichtenstein
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

8.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

Review 9.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

Review 10.  Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?

Authors:  Patrick S Moore; Yuan Chang
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.